siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in mice.
Acute Kidney Injury
/ etiology
Animals
CD40 Antigens
/ antagonists & inhibitors
Disease Models, Animal
Fibrosis
Gene Expression
Gene Silencing
Humans
Inflammation Mediators
/ antagonists & inhibitors
Kidney
/ pathology
Male
Mice
Mice, Inbred C57BL
RNA, Messenger
/ genetics
RNA, Small Interfering
/ genetics
Ureteral Obstruction
/ complications
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
11
2018
accepted:
28
03
2019
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
6
2
2020
Statut:
epublish
Résumé
The costimulatory CD40-CD40L pathway plays a role in kidney inflammation. We have previously reported that renal CD40 upregulation precedes cellular interstitial infiltrate and fibrosis in the unilateral ureteral obstruction (UUO) model. Here we sought to evaluate whether the administration of siRNA-CD40 has a therapeutic effect in a reversible unilateral ureteral obstruction (D-UUO) mice model. Eight week-old C57BL6J male mice were divided into four groups: Vehicle (Phosphate-buffered saline) (n = 8); siRNA SC (non-specific siRNA) (n = 6); siRNA-CD40 (n = 8) and WT (wild type) (n = 6) mice. UUO was performed with a microvascular clamp. At day 3 after surgery, the ureteral clamp was removed and nephrectomy of the contralateral kidney was performed. Immediately, PBS, siRNA SC (50μg) or siRNA-CD40 (50μg) was administrated via the tail vein. Mice were killed 48h hours after the siRNA or saline administration. Wild type (WT) mice were used as controls. Blood samples were collected for measuring creatinine and blood urea nitrogen (BUN). Histology and kidney mRNA expression were performed. The administration of siRNA-CD40 reduced significantly the severity of acute renal failure associated with UUO. Pathologic analysis showed reduction of tubular dilation, interstitial fibrosis, F4/80 macrophage and CD3 (T cell) infiltration in animals treated with siRNA-CD40. Furthermore, kidney mRNA gene expression analysis showed significantly lower levels of macrophage markers (F4/80 and Mannose receptor), fibrosis matrix proteins (Fibronectin, MMP-9, Collagen IV and α-SMA), pro-inflammatory cytokines (iNOS and MCP-1) and the pro-fibrotic molecule TGF-β1 in siRNA-CD40. The administration of siRNA-CD40 therapy reduces the severity of the acute kidney injury induced by obstructive uropathy and promotes kidney repair. This strategy seems suitable to be tested in humans.
Sections du résumé
BACKGROUND
The costimulatory CD40-CD40L pathway plays a role in kidney inflammation. We have previously reported that renal CD40 upregulation precedes cellular interstitial infiltrate and fibrosis in the unilateral ureteral obstruction (UUO) model. Here we sought to evaluate whether the administration of siRNA-CD40 has a therapeutic effect in a reversible unilateral ureteral obstruction (D-UUO) mice model.
METHODS
Eight week-old C57BL6J male mice were divided into four groups: Vehicle (Phosphate-buffered saline) (n = 8); siRNA SC (non-specific siRNA) (n = 6); siRNA-CD40 (n = 8) and WT (wild type) (n = 6) mice. UUO was performed with a microvascular clamp. At day 3 after surgery, the ureteral clamp was removed and nephrectomy of the contralateral kidney was performed. Immediately, PBS, siRNA SC (50μg) or siRNA-CD40 (50μg) was administrated via the tail vein. Mice were killed 48h hours after the siRNA or saline administration. Wild type (WT) mice were used as controls. Blood samples were collected for measuring creatinine and blood urea nitrogen (BUN). Histology and kidney mRNA expression were performed.
RESULTS
The administration of siRNA-CD40 reduced significantly the severity of acute renal failure associated with UUO. Pathologic analysis showed reduction of tubular dilation, interstitial fibrosis, F4/80 macrophage and CD3 (T cell) infiltration in animals treated with siRNA-CD40. Furthermore, kidney mRNA gene expression analysis showed significantly lower levels of macrophage markers (F4/80 and Mannose receptor), fibrosis matrix proteins (Fibronectin, MMP-9, Collagen IV and α-SMA), pro-inflammatory cytokines (iNOS and MCP-1) and the pro-fibrotic molecule TGF-β1 in siRNA-CD40.
CONCLUSIONS
The administration of siRNA-CD40 therapy reduces the severity of the acute kidney injury induced by obstructive uropathy and promotes kidney repair. This strategy seems suitable to be tested in humans.
Identifiants
pubmed: 30978213
doi: 10.1371/journal.pone.0215232
pii: PONE-D-18-32645
pmc: PMC6461348
doi:
Substances chimiques
CD40 Antigens
0
Inflammation Mediators
0
RNA, Messenger
0
RNA, Small Interfering
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0215232Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lab Invest. 2013 Apr;93(4):434-49
pubmed: 23358111
Blood. 2008 Nov 1;112(9):3624-37
pubmed: 18669876
Pediatr Nephrol. 1990 Jul;4(4):442-4
pubmed: 2206915
Diabetologia. 2012 Jul;55(7):2059-68
pubmed: 22460762
Cell Physiol Biochem. 2016;38(5):1761-74
pubmed: 27161221
Pediatr Nephrol. 2003 Jun;18(6):576-606
pubmed: 12720078
PLoS One. 2013 Jun 14;8(6):e65068
pubmed: 23799000
Atherosclerosis. 2016 Dec;255:80-89
pubmed: 27835742
Gene Ther. 2011 Oct;18(10):945-52
pubmed: 21472009
Kidney Int. 2015 Sep;88(3):538-49
pubmed: 25993320
Theranostics. 2015 Jan 01;5(2):110-23
pubmed: 25553102
J Am Soc Nephrol. 2010 Nov;21(11):1819-34
pubmed: 20864689
Curr Pharm Des. 2016;22(30):4651-4657
pubmed: 27510493
Exp Nephrol. 2000 Jul-Oct;8(4-5):203-7
pubmed: 10940717
Am J Physiol Renal Physiol. 2010 Apr;298(4):F1024-32
pubmed: 20089676
Curr Opin Pediatr. 2006 Apr;18(2):153-60
pubmed: 16601495
Am J Physiol Renal Physiol. 2013 Feb 15;304(4):F432-9
pubmed: 23220725
Kidney Int. 2008 Apr;73(7):885-9
pubmed: 18200000
Transplantation. 2005 May 15;79(9):1078-83
pubmed: 15880047
Kidney Int. 2016 Apr;89(4):738-40
pubmed: 26994569
Immunol Lett. 2013 Jun;153(1-2):58-61
pubmed: 23892087
Immunol Rev. 2009 May;229(1):152-72
pubmed: 19426221
Clin Kidney J. 2016 Dec;9(6):765-771
pubmed: 27994852
Nat Rev Nephrol. 2014 Sep;10(9):493-503
pubmed: 24981817
Kidney Int. 2002 Jun;61(6):2033-43
pubmed: 12028444
J Exp Med. 1995 Jul 1;182(1):33-40
pubmed: 7540655
J Am Soc Nephrol. 2005 Dec;16(12):3623-30
pubmed: 16221872
Cell Physiol Biochem. 2017;42(5):1945-1960
pubmed: 28793288
Am J Physiol Renal Physiol. 2015 Mar 1;308(5):F459-72
pubmed: 25537742
Cells Tissues Organs. 2007;185(1-3):222-31
pubmed: 17587828
Kidney Int. 2009 Jun;75(11):1145-1152
pubmed: 19340094